As an individual who holds a Ph.D. in Genetics and as co-founder and current CEO of Seattle Genetics, Clay Siegall is at the forefront of developing twenty-first-century therapies for cancer treatment. Adcetris, the company’s flagship drug fights lymphomas, while a dozen other drugs in the works will fight other cancers, including bladder and breast cancer. In 2016, Forbes named Siegall’s Seattle Genetics as number 71 on their Innovative Growth Companies list for their development of monoclonal antibody-based cancer therapies.
When Seattle PI spoke with Siegall about his Bothell, Washington-based Company, he admitted that his father had passed away due to brain cancer, which prompted him to help develop better therapies that made chemotherapy less toxic to the body. He co-founded Seattle Genetics in 1997 after Bristol Myer’s, the company that he relocated to Seattle to work at, closed their Seattle operations. After raising $37 million in venture capital funding, Siegall and his team focused on developing products for the ADC market. By 2011, Adcetris earned FDA approval and now, it is available in more than 45 countries worldwide. Seattle Genetics sells their new type of ADC platform in the U.S. and Canada, while Takeda Oncology markets Adcetris in other countries.
Siegall took the biotechnology company public in 2001, bringing in an additional $51 million in capital. Collaborations with other companies, including Abbott, Bayer, GlaxoSmithKline and Pfizer for its ADC technology bring in additional capital. Seattle Genetic’s collaboration with Pfizer alone brought in $8 million upfront, with additional payments and royalties likely. Under Siegall’s leadership, Seattle Genetics has raised over $145 million from licensing their proprietary technology ADC platform.